SlideShare uma empresa Scribd logo
1 de 5
Baixar para ler offline
Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead
to Erosion of Brand Share
Statins Market to 2018 Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead
to Erosion of Brand Share
Summary
GBI Research, the leading business intelligence provider, has released its latest research, Statins Market to
2018 Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand
Share, which provides insights into the global statins market until 2018. The report is built using data and
information sourced from proprietary databases, primary and secondary research, and in-house analysis by
GBI Researchs team of industry experts. The report provides an in-depth analysis of the global statins market
for dyslipidemia. The report gives insights into the share of generics in the global statins market for the years
2011 and 2018. The report examines the dyslipidemia treatment usage patterns in the US, the top five
countries of Europe (The UK, France, Germany, Spain and Italy), and Japan. In addition to the global market
landscape for statins, the report also provides details of the geographical distribution of statins sales in the
major markets, including the US, the top five countries of Europe, and Japan. The report also includes insights
into the statins R&D product pipeline, and explores the competitive landscape, including major players in the
statins market. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing and
co-development deals that have taken place in the statins market.
Statins have dominated the global dyslipidemia therapeutics market for the last few decades. The National
Cholesterol Education Program (NECP) and European Society of Cardiology/European Atherosclerosis
Society (ESC/EAS) guidelines have recommended the use of statins as the first choice of pharmacotherapy for
the treatment of dyslipidemia. The global statins market, valued at $20.5 billion in 2011, is forecast to decline
at a negative Compound Annual Growth Rate (CAGR) of 7.2% over the next seven years, to reach $12.2
billion by 2018. The highly consolidated statins market is expected to become increasingly competitive in the
forecast period, with the patent expiries of (atorvastatin calcium), Vytorin (Ezetimibe/simvastatin), Lescol
(fluvastatin) and Crestor (rosuvastatin), followed by severe generic erosion. GBI Research estimates that the
generic sector in the global statins market will grow significantly in the future and will pose tough competition
to new molecules.
Scope
Data and analysis on the statins market in the leading geographies of the world the US, the UK, Germany,
France, Italy, Spain, and Japan. Annualized market data for the statins market from 2004 to 2011, with
forecasts to 2018. Market data on the geographical landscape and therapeutic landscape, including market size,
market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population,
treatment-seeking population, diagnosis population and prescription population. Share of generics in the
global statins market. Key drivers and restraints that have had a significant impact on the global statins
market. The competitive landscape of the global statins market, including top companies benchmarking. The
key companies studied in this report are Pfizer, AstraZeneca, Merck and Novartis. Key M&A activities and
licensing agreements that took place in the statins market.
Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
Reasons to buy
Align their product portfolio to the markets with high growth potential Build effective strategies to launch
their pipeline products by identifying potential geographies Exploit in-licensing and out-licensing
opportunities by identifying products that might fill their portfolio gaps Develop key strategic initiatives by
studying the key strategies of top competitors Devise more tailored country-specific strategies through the
understanding of key drivers and barriers and the market potential of each indication for different territories
Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong
growth Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class
molecules which are safer and more efficacious
table Of Contents
1 Table Of Contents
1 Table Of Contents 5
1.1 List Of Tables 7
1.2 List Of Figures 7
2 Statins Market To 2018 - Introduction 8
3 Statins Market To 2018 - Global Statins Market 9
3.1 Introduction 9
3.2 Global Market Forecast 10
3.2.1 Branded And Generic Market Share 12
3.3 Annual Cost Of Treatment 13
3.4 Treatment Usage Patterns 14
3.4.1 Disease Population 15
3.4.2 Treatment Seeking Population 15
3.4.3 Diagnosed Population 15
3.4.4 Prescription Population 15
3.5 Drivers And Restraints To The Statins Market 16
3.5.1 Drivers To The Statins Market 16
3.5.2 Restraints To The Statins Market 17
3.6 Major Marketed Products 19
3.6.1 Crestor (rosuvastatin Calcium) 19
3.6.2 Lipitor (atorvastatin Calcium) 20
3.6.3 Vytorin (ezetimibe/simvastatin) 21
3.6.4 Zocor (simvastatin) 22
3.6.5 Livalo (pitavastatin Calcium) 22
3.6.6 Lescol Xl (fluvastatin Sodium) 23
Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
3.6.7 Pravachol (pravastatin Sodium) 24
4 Statins Market To 2018 - Statins Market In The Us 25
4.1 Market 25
4.2 Annual Cost Of Therapy (act) 27
4.3 Treatment Usage Pattern 28
4.3.1 Diseased Population 29
4.3.2 Treatment Seeking Population 29
4.3.3 Diagnosed Population 29
4.3.4 Patients On Statins Therapy 29
5 Statins Market To 2018 - Statins Market In The Top Five Countries Of Europe 30
5.1 Market 30
5.2 Annual Cost Of Therapy 33
5.3 Treatment Usage Pattern 34
5.3.1 Diseased Population 35
5.3.2 Treatment Seeking Population 35
5.3.3 Diagnosed Population 35
5.3.4 Patients On Statins Therapy 35
6 Statins Market To 2018 - Statins Market In Japan 36
6.1 Market 36
6.2 Annual Cost Of Therapy 38
6.3 Treatment Usage Pattern 40
6.3.1 Diseased Population 41
6.3.2 Treatment Seeking Population 41
6.3.3 Diagnosed Population 41
6.3.4 Patients On Statins Therapy 41
7 Statins Market To 2018 - Product Pipeline Anlaysis 42
7.1 Introduction 42
7.2 Pipeline Analysis 42
8 Statins Market To 2018 - Competitive Landscape 43
8.1 Pfizer Inc. 44
8.1.1 Company Overview 44
8.1.2 Swot Analysis 44
8.2 Astrazeneca Plc (astrazeneca) 45
Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
8.2.1 Company Overview 45
8.2.2 Swot Analysis 45
8.3 Merck & Co Inc 46
8.3.1 Company Overview 46
8.3.2 Swot Analysis 46
8.4 Novartis Ag (novartis) 47
8.4.1 Company Overview 47
8.4.2 Swot Analysis 47
9 Statins Market To 2018 - Strategic Consolidation 48
9.1 Merger And Acquisition (m&a) Deals 48
9.2 Licensing Deals 49
9.2.1 Licensing Deals By Geography 49
9.3 Co-development Deals 51
10 Statins Market To 2018 - Appendix 52
10.1 Market Definitions 52
10.2 Abbreviations 52
10.3 Bibliography 55
10.4 Research Methodology 56
10.4.1 Coverage 56
10.4.2 Secondary Research 56
10.4.3 Primary Research 57
10.4.4 Therapeutic Landscape 57
10.4.5 Geographical Landscape 60
10.4.6 Pipeline Analysis 60
10.4.7 Competitive Landscape 60
10.5 Expert Panel Validation 60
10.6 Contact Us 60
10.7 Disclaimer 60
About Us:
Transparency Market Research is a market intelligence company providing global business information
reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of
Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.
Contact:
ResearchMoz
Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Blog: http://researchmoz.blogspot.com/
Website: http://www.researchmoz.us/
Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Mais conteúdo relacionado

Mais de Ambikabasa

Uveitis global clinical trials review, h1, 2015
Uveitis global clinical trials review, h1, 2015Uveitis global clinical trials review, h1, 2015
Uveitis global clinical trials review, h1, 2015Ambikabasa
 
Cleco corporation power plants and swot analysis, 2015 update
Cleco corporation   power plants and swot analysis, 2015 updateCleco corporation   power plants and swot analysis, 2015 update
Cleco corporation power plants and swot analysis, 2015 updateAmbikabasa
 
Philippines telecoms, mobile and broadband
Philippines   telecoms, mobile and broadbandPhilippines   telecoms, mobile and broadband
Philippines telecoms, mobile and broadbandAmbikabasa
 
Addiction pipeline review, h1 2015
Addiction   pipeline review, h1 2015Addiction   pipeline review, h1 2015
Addiction pipeline review, h1 2015Ambikabasa
 
Arrhythmias pipeline review, h1 2015
Arrhythmias   pipeline review, h1 2015Arrhythmias   pipeline review, h1 2015
Arrhythmias pipeline review, h1 2015Ambikabasa
 
Ocular pain pipeline review, h1 2015
Ocular pain   pipeline review, h1 2015Ocular pain   pipeline review, h1 2015
Ocular pain pipeline review, h1 2015Ambikabasa
 
Paroxysmal nocturnal hemoglobinuria pipeline review, h1 2015
Paroxysmal nocturnal hemoglobinuria   pipeline review, h1 2015Paroxysmal nocturnal hemoglobinuria   pipeline review, h1 2015
Paroxysmal nocturnal hemoglobinuria pipeline review, h1 2015Ambikabasa
 
Rhabdomyosarcoma pipeline review, h1 2015
Rhabdomyosarcoma   pipeline review, h1 2015Rhabdomyosarcoma   pipeline review, h1 2015
Rhabdomyosarcoma pipeline review, h1 2015Ambikabasa
 
Raynauds disease pipeline review, h1 2015
Raynauds disease   pipeline review, h1 2015Raynauds disease   pipeline review, h1 2015
Raynauds disease pipeline review, h1 2015Ambikabasa
 
Travelers diarrhea pipeline review, h1 2015
Travelers diarrhea   pipeline review, h1 2015Travelers diarrhea   pipeline review, h1 2015
Travelers diarrhea pipeline review, h1 2015Ambikabasa
 
Herpes zoster (shingles) pipeline review, h1 2015
Herpes zoster (shingles)   pipeline review, h1 2015Herpes zoster (shingles)   pipeline review, h1 2015
Herpes zoster (shingles) pipeline review, h1 2015Ambikabasa
 
Emphysema pipeline review, h1 2015
Emphysema   pipeline review, h1 2015Emphysema   pipeline review, h1 2015
Emphysema pipeline review, h1 2015Ambikabasa
 
Cerebral infarction (brain infarction) pipeline review, h1 2015
Cerebral infarction (brain infarction)   pipeline review, h1 2015Cerebral infarction (brain infarction)   pipeline review, h1 2015
Cerebral infarction (brain infarction) pipeline review, h1 2015Ambikabasa
 
Seborrhea pipeline review, h1 2015
Seborrhea   pipeline review, h1 2015Seborrhea   pipeline review, h1 2015
Seborrhea pipeline review, h1 2015Ambikabasa
 
Respiratory depression pipeline review, h1 2015
Respiratory depression   pipeline review, h1 2015Respiratory depression   pipeline review, h1 2015
Respiratory depression pipeline review, h1 2015Ambikabasa
 
H1 n1 infection pipeline review, h1 2015
H1 n1 infection   pipeline review, h1 2015H1 n1 infection   pipeline review, h1 2015
H1 n1 infection pipeline review, h1 2015Ambikabasa
 
Nicotine addiction pipeline review, h1 2015
Nicotine addiction   pipeline review, h1 2015Nicotine addiction   pipeline review, h1 2015
Nicotine addiction pipeline review, h1 2015Ambikabasa
 
Food allergy pipeline review, h1 2015
Food allergy   pipeline review, h1 2015Food allergy   pipeline review, h1 2015
Food allergy pipeline review, h1 2015Ambikabasa
 
Uveal melanoma pipeline review, h1 2015
Uveal melanoma   pipeline review, h1 2015Uveal melanoma   pipeline review, h1 2015
Uveal melanoma pipeline review, h1 2015Ambikabasa
 
Tillotts pharma ag product pipeline review - 2015
Tillotts pharma ag   product pipeline review - 2015Tillotts pharma ag   product pipeline review - 2015
Tillotts pharma ag product pipeline review - 2015Ambikabasa
 

Mais de Ambikabasa (20)

Uveitis global clinical trials review, h1, 2015
Uveitis global clinical trials review, h1, 2015Uveitis global clinical trials review, h1, 2015
Uveitis global clinical trials review, h1, 2015
 
Cleco corporation power plants and swot analysis, 2015 update
Cleco corporation   power plants and swot analysis, 2015 updateCleco corporation   power plants and swot analysis, 2015 update
Cleco corporation power plants and swot analysis, 2015 update
 
Philippines telecoms, mobile and broadband
Philippines   telecoms, mobile and broadbandPhilippines   telecoms, mobile and broadband
Philippines telecoms, mobile and broadband
 
Addiction pipeline review, h1 2015
Addiction   pipeline review, h1 2015Addiction   pipeline review, h1 2015
Addiction pipeline review, h1 2015
 
Arrhythmias pipeline review, h1 2015
Arrhythmias   pipeline review, h1 2015Arrhythmias   pipeline review, h1 2015
Arrhythmias pipeline review, h1 2015
 
Ocular pain pipeline review, h1 2015
Ocular pain   pipeline review, h1 2015Ocular pain   pipeline review, h1 2015
Ocular pain pipeline review, h1 2015
 
Paroxysmal nocturnal hemoglobinuria pipeline review, h1 2015
Paroxysmal nocturnal hemoglobinuria   pipeline review, h1 2015Paroxysmal nocturnal hemoglobinuria   pipeline review, h1 2015
Paroxysmal nocturnal hemoglobinuria pipeline review, h1 2015
 
Rhabdomyosarcoma pipeline review, h1 2015
Rhabdomyosarcoma   pipeline review, h1 2015Rhabdomyosarcoma   pipeline review, h1 2015
Rhabdomyosarcoma pipeline review, h1 2015
 
Raynauds disease pipeline review, h1 2015
Raynauds disease   pipeline review, h1 2015Raynauds disease   pipeline review, h1 2015
Raynauds disease pipeline review, h1 2015
 
Travelers diarrhea pipeline review, h1 2015
Travelers diarrhea   pipeline review, h1 2015Travelers diarrhea   pipeline review, h1 2015
Travelers diarrhea pipeline review, h1 2015
 
Herpes zoster (shingles) pipeline review, h1 2015
Herpes zoster (shingles)   pipeline review, h1 2015Herpes zoster (shingles)   pipeline review, h1 2015
Herpes zoster (shingles) pipeline review, h1 2015
 
Emphysema pipeline review, h1 2015
Emphysema   pipeline review, h1 2015Emphysema   pipeline review, h1 2015
Emphysema pipeline review, h1 2015
 
Cerebral infarction (brain infarction) pipeline review, h1 2015
Cerebral infarction (brain infarction)   pipeline review, h1 2015Cerebral infarction (brain infarction)   pipeline review, h1 2015
Cerebral infarction (brain infarction) pipeline review, h1 2015
 
Seborrhea pipeline review, h1 2015
Seborrhea   pipeline review, h1 2015Seborrhea   pipeline review, h1 2015
Seborrhea pipeline review, h1 2015
 
Respiratory depression pipeline review, h1 2015
Respiratory depression   pipeline review, h1 2015Respiratory depression   pipeline review, h1 2015
Respiratory depression pipeline review, h1 2015
 
H1 n1 infection pipeline review, h1 2015
H1 n1 infection   pipeline review, h1 2015H1 n1 infection   pipeline review, h1 2015
H1 n1 infection pipeline review, h1 2015
 
Nicotine addiction pipeline review, h1 2015
Nicotine addiction   pipeline review, h1 2015Nicotine addiction   pipeline review, h1 2015
Nicotine addiction pipeline review, h1 2015
 
Food allergy pipeline review, h1 2015
Food allergy   pipeline review, h1 2015Food allergy   pipeline review, h1 2015
Food allergy pipeline review, h1 2015
 
Uveal melanoma pipeline review, h1 2015
Uveal melanoma   pipeline review, h1 2015Uveal melanoma   pipeline review, h1 2015
Uveal melanoma pipeline review, h1 2015
 
Tillotts pharma ag product pipeline review - 2015
Tillotts pharma ag   product pipeline review - 2015Tillotts pharma ag   product pipeline review - 2015
Tillotts pharma ag product pipeline review - 2015
 

Statins Market Trends to 2018 | Researchmoz.us

  • 1. Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share Statins Market to 2018 Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share Summary GBI Research, the leading business intelligence provider, has released its latest research, Statins Market to 2018 Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share, which provides insights into the global statins market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth analysis of the global statins market for dyslipidemia. The report gives insights into the share of generics in the global statins market for the years 2011 and 2018. The report examines the dyslipidemia treatment usage patterns in the US, the top five countries of Europe (The UK, France, Germany, Spain and Italy), and Japan. In addition to the global market landscape for statins, the report also provides details of the geographical distribution of statins sales in the major markets, including the US, the top five countries of Europe, and Japan. The report also includes insights into the statins R&D product pipeline, and explores the competitive landscape, including major players in the statins market. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing and co-development deals that have taken place in the statins market. Statins have dominated the global dyslipidemia therapeutics market for the last few decades. The National Cholesterol Education Program (NECP) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines have recommended the use of statins as the first choice of pharmacotherapy for the treatment of dyslipidemia. The global statins market, valued at $20.5 billion in 2011, is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 7.2% over the next seven years, to reach $12.2 billion by 2018. The highly consolidated statins market is expected to become increasingly competitive in the forecast period, with the patent expiries of (atorvastatin calcium), Vytorin (Ezetimibe/simvastatin), Lescol (fluvastatin) and Crestor (rosuvastatin), followed by severe generic erosion. GBI Research estimates that the generic sector in the global statins market will grow significantly in the future and will pose tough competition to new molecules. Scope Data and analysis on the statins market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan. Annualized market data for the statins market from 2004 to 2011, with forecasts to 2018. Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment-seeking population, diagnosis population and prescription population. Share of generics in the global statins market. Key drivers and restraints that have had a significant impact on the global statins market. The competitive landscape of the global statins market, including top companies benchmarking. The key companies studied in this report are Pfizer, AstraZeneca, Merck and Novartis. Key M&A activities and licensing agreements that took place in the statins market. Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
  • 2. Reasons to buy Align their product portfolio to the markets with high growth potential Build effective strategies to launch their pipeline products by identifying potential geographies Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps Develop key strategic initiatives by studying the key strategies of top competitors Devise more tailored country-specific strategies through the understanding of key drivers and barriers and the market potential of each indication for different territories Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious table Of Contents 1 Table Of Contents 1 Table Of Contents 5 1.1 List Of Tables 7 1.2 List Of Figures 7 2 Statins Market To 2018 - Introduction 8 3 Statins Market To 2018 - Global Statins Market 9 3.1 Introduction 9 3.2 Global Market Forecast 10 3.2.1 Branded And Generic Market Share 12 3.3 Annual Cost Of Treatment 13 3.4 Treatment Usage Patterns 14 3.4.1 Disease Population 15 3.4.2 Treatment Seeking Population 15 3.4.3 Diagnosed Population 15 3.4.4 Prescription Population 15 3.5 Drivers And Restraints To The Statins Market 16 3.5.1 Drivers To The Statins Market 16 3.5.2 Restraints To The Statins Market 17 3.6 Major Marketed Products 19 3.6.1 Crestor (rosuvastatin Calcium) 19 3.6.2 Lipitor (atorvastatin Calcium) 20 3.6.3 Vytorin (ezetimibe/simvastatin) 21 3.6.4 Zocor (simvastatin) 22 3.6.5 Livalo (pitavastatin Calcium) 22 3.6.6 Lescol Xl (fluvastatin Sodium) 23 Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
  • 3. 3.6.7 Pravachol (pravastatin Sodium) 24 4 Statins Market To 2018 - Statins Market In The Us 25 4.1 Market 25 4.2 Annual Cost Of Therapy (act) 27 4.3 Treatment Usage Pattern 28 4.3.1 Diseased Population 29 4.3.2 Treatment Seeking Population 29 4.3.3 Diagnosed Population 29 4.3.4 Patients On Statins Therapy 29 5 Statins Market To 2018 - Statins Market In The Top Five Countries Of Europe 30 5.1 Market 30 5.2 Annual Cost Of Therapy 33 5.3 Treatment Usage Pattern 34 5.3.1 Diseased Population 35 5.3.2 Treatment Seeking Population 35 5.3.3 Diagnosed Population 35 5.3.4 Patients On Statins Therapy 35 6 Statins Market To 2018 - Statins Market In Japan 36 6.1 Market 36 6.2 Annual Cost Of Therapy 38 6.3 Treatment Usage Pattern 40 6.3.1 Diseased Population 41 6.3.2 Treatment Seeking Population 41 6.3.3 Diagnosed Population 41 6.3.4 Patients On Statins Therapy 41 7 Statins Market To 2018 - Product Pipeline Anlaysis 42 7.1 Introduction 42 7.2 Pipeline Analysis 42 8 Statins Market To 2018 - Competitive Landscape 43 8.1 Pfizer Inc. 44 8.1.1 Company Overview 44 8.1.2 Swot Analysis 44 8.2 Astrazeneca Plc (astrazeneca) 45 Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
  • 4. 8.2.1 Company Overview 45 8.2.2 Swot Analysis 45 8.3 Merck & Co Inc 46 8.3.1 Company Overview 46 8.3.2 Swot Analysis 46 8.4 Novartis Ag (novartis) 47 8.4.1 Company Overview 47 8.4.2 Swot Analysis 47 9 Statins Market To 2018 - Strategic Consolidation 48 9.1 Merger And Acquisition (m&a) Deals 48 9.2 Licensing Deals 49 9.2.1 Licensing Deals By Geography 49 9.3 Co-development Deals 51 10 Statins Market To 2018 - Appendix 52 10.1 Market Definitions 52 10.2 Abbreviations 52 10.3 Bibliography 55 10.4 Research Methodology 56 10.4.1 Coverage 56 10.4.2 Secondary Research 56 10.4.3 Primary Research 57 10.4.4 Therapeutic Landscape 57 10.4.5 Geographical Landscape 60 10.4.6 Pipeline Analysis 60 10.4.7 Competitive Landscape 60 10.5 Expert Panel Validation 60 10.6 Contact Us 60 10.7 Disclaimer 60 About Us: Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Contact: ResearchMoz Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
  • 5. 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Blog: http://researchmoz.blogspot.com/ Website: http://www.researchmoz.us/ Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share